Conference Discussion Questions Big Pharma's True Motivations for Pursuing Personalized Medicine
December 02, 2009
Conference Discussion Questions Big Pharma's True Motivations for Pursuing Personalized Medicine
At a meeting hosted by the Partners HealthCare Center for Personalized Genetic Medicine last month, the events leading up to the re-labeling for colorectal cancer drugs Vectibix and Erbitux sparked discussion among participants about what Amgen and Bristol-Myers Squibb/ImClone knew about the drugs and when.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PMC Asks FDA to Issue New Guidance Reflecting Rapidly Evolving Rx/Dx Co-development Landscape
December 16, 2009 / Pharmacogenomics Reporter - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - Qiagen Enters Companion Dx Market with Approval of KRAS Test Kit for Erbitux; LDT Impact Unknown
July 11, 2012 / Pharmacogenomics Reporter - FDA Update to Erbitux, Vectibix Labels Encourages Rx/Dx Co-development, Industry Expert Says
July 22, 2009 / Pharmacogenomics Reporter - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter